Research programme: autologous T-cell therapies - Adaptimmune

Drug Profile

Research programme: autologous T-cell therapies - Adaptimmune

Alternative Names: Affinity-enhanced T-cell receptors - Adaptimmune; Allogenic T-cell therapies - Adaptimmune; Cytotoxic T-lymphocytes stimulants - Adaptimmune; PRAME; Preferentially expressed antigen in melanoma

Latest Information Update: 01 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adaptimmune
  • Class Cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer
  • Research Diabetes mellitus; Hepatitis C; Immunological disorders

Most Recent Events

  • 25 Apr 2017 Adaptimmune plans a phase I trial for Hepatocellular carcinoma (Late-stage disease, In adults, In the elderly, Second-line therapy or greater) in USA (NCT03132792)
  • 20 Dec 2016 Adaptimmune Therapeutics and Bellicum Pharmaceuticals collaborate to evaluate, develop, and commercialise T-cell therapies
  • 21 Jun 2016 Adaptimmune Therapeutics and Thermo Fischer Scientific enter into a new 10-year agreement for the use of Dynabeads CD3/CD28 Cell Therapy System (CTS™) to manufacture SPEAR™ T-cell therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top